Lung cancer therapy with in vivo-generated dendritic cells

Institution:	University of California, Los Angeles
Investigator(s):	Saroj Basak, Ph.D.
Award Cycle:	2001 (Cycle 10)	Grant #: 10KT-0086	Award: $225,000
Subject Area:	Cancer
Award Type:	New Investigator Awards

Abstracts

Initial Award Abstract

Lung Cancer is a major cause of tobacco-related death all over the world and new strategies are being developed for its treatment. Our research group has developed an immune-based treatment in which patients take a daily injection of immune-boosting growth factors. These growth factors increase the number and function of special white blood cells, called dendritic cells, that can be used to jump start the immune system so that it recognizes and destroys cancer cells. Preliminary studies suggest that this approach is well tolerated in cancer patients and can stimulate their natural anti-cancer defenses.

We have developed a mouse model so that new combinations of immune boosting growth factors can be tested and the mechanisms by which they activate the dendritic cells understood. Specifically, we will combine these growth factors with an anti-tumor vaccine and with drugs that recruit the activated dendritic cells to the tumor site. These studies should provide insight into how the immune system fights cancer and provide important information for designing new clinical trials for lung cancer patients. If we are successful in our proposed research procedure, it has the potential to provide a simple, safe and reliable treatment for lung cancer.

Publications

Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage- colony- stimulating factor and interleukin-4.
Periodical: Blood			Index Medicus:
Authors: Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM and Roth MD				ART
Yr: 2002	Vol: 99	Nbr: 8	Abs:	Pg: 2869-2879

Biological and immunological properties of helper-dependent adenovirus (HD-AdV) when used to transduce dendritic cells.
Periodical: Proceedings of the American Association for Cancer Research			Index Medicus:
Authors: Harui A, Kierstscher SM, Cheng Q, Roth MD, Mitani K, and Basak S				ABS
Yr: 2002	Vol: 43	Nbr:	Abs:	Pg:

Evaluation of helper dependant adenovirus (HD-AdV) for efficient vaccination strategies.
Periodical: American Association for Cancer Research			Index Medicus:
Authors: Harui A, Kierstscher SM, Roth MD< Mitani K, Basak S				ABS
Yr: 2003	Vol:	Nbr:	Abs:	Pg:

Developing new gene therapy approaches to lung cancer treatment
Periodical: TRDRP Annual Report to the State of California Legislature			Index Medicus:
Authors: Harui A, Roth MD, Mitani K, Basak S				ABS
Yr: 2002	Vol:	Nbr:	Abs:	Pg:

Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage- colony- stimulating factor and interleukin-4.
Periodical: Blood			Index Medicus:
Authors: Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM and Roth MD				ART
Yr: 2002	Vol: 99	Nbr: 8	Abs:	Pg: 2869-2879

Biological and immunological properties of helper-dependent adenovirus (HD-AdV) when used to transduce dendritic cells.
Periodical: Proceedings of the American Association for Cancer Research			Index Medicus:
Authors: Harui A, Kierstscher SM, Cheng Q, Roth MD, Mitani K, and Basak S				ABS
Yr: 2002	Vol: 43	Nbr:	Abs:	Pg:

Evaluation of helper dependant adenovirus (HD-AdV) for efficient vaccination strategies.
Periodical: American Association for Cancer Research			Index Medicus:
Authors: Harui A, Kierstscher SM, Roth MD< Mitani K, Basak S				ABS
Yr: 2003	Vol:	Nbr:	Abs:	Pg:

Developing new gene therapy approaches to lung cancer treatment
Periodical: TRDRP Annual Report to the State of California Legislature			Index Medicus:
Authors: Harui A, Roth MD, Mitani K, Basak S				ABS
Yr: 2002	Vol:	Nbr:	Abs:	Pg: